Do cD34 , CD4 , and CD8 cell doses influence engraftment , graft-versus-host disease , or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies?
G-PBMC graft content does not influence outcomes after myeloablative AHCT. In particular, no significant association between extensive chronic GVHD was identified with any G-PBMC cell dose, including CD34.
This study, designed as a proof of principle, indicated that the LDT is an accurate, robust and automated assay, which adequately and reliably identifies patients presenting with small fiber neuropathy, and therefore has potential for use in large scale clinical studies.